癌症治疗中使用复制缺陷腺病毒介导的干扰素基因疗法可能预期具有良好的利益风险平衡。
A Favorable Benefit-Risk Balance Maybe Expected with the Replication-defective Adenovirus-mediated Interferon Gene Therapy for Cancer Treatment.
发表日期：2023 Mar 01
作者：
Albert Qin
来源：
HUMAN GENE THERAPY
摘要：
两个月前，美国FDA批准了一种非复制腺病毒编码干扰素阿尔法-2b（IFN-a2b）的治疗高风险结核卡介苗（BCG）不敏感的非肌肉侵袭性膀胱癌的药物。这篇致编辑的信提供了使用复制缺陷腺病毒介导的干扰素治疗癌症的见解，并解释了为什么可以预期使用这种方法会产生积极的临床利益风险概况。这种方法可以导致更多的基因治疗获得癌症治疗批准。
Two months ago, the US FDA has approved a non-replicating adenovirus encoding interferon alfa-2b (IFN-a2b) for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. This LETTER TO THE EDITOR provides the insights regarding the use of a replication-defective adenovirus-mediated IFN therapy for cancer treatment and explains why a positive clinical benefit-risk profile can be expected from using this approach. This approach can lead to more gene therapy approvals for cancer treatment.